ArticleDiagnostic and interventional radiology (Ankara, Turkey)2025
Early prediction of neoadjuvant chemotherapy efficacy among patients with triple-negative breast cancer using an ultrasound-based radiomics nomogram.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and validate a radiomics nomogram based on early ultrasound (US) imaging for predicting pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC).
methodsThis retrospective study included 328 patients with TNBC treated between September 2019 and January 2024, divided into a training cohort (n = 230) and a validation cohort (n = 98). Clinicopathologic data, US features before NAC, tumor volume reduction (TVR) after two cycles of NAC, and radiomics features were collected. Multiple logistic regression was applied to identify the potential predictors of pCR. The efficacy of the nomogram was evaluated through the receiver operating characteristic, calibration, and decision curve analyses. The study was approved by the ethics committee on February 28, 2024, with approval number 2023-SR-799, and the requirement for informed consent was waived.
resultsTwelve features were selected to construct the radiomics signature (RS). The nomogram, incorporating tumor histologic grade, TVR, and RS, yielded an area under the curve of 0.856 [95% confidence interval (CI), 0.807-0.905] in the training cohort and 0.836 (95% CI, 0.749-0.923) in the validation cohort, outperforming both the clinico-ultrasonic and RS models. The calibration and decision curves confirmed the nomogram's excellent calibration and clinical utility.
conclusionThe nomogram, which includes US characteristics, clinical variables, and radiomics features, exhibited satisfactory performance in predicting NAC efficacy in patients with TNBC. CLINICAL SIGNIFICANCE: The US-based radiomics nomogram, incorporating histologic grade, TVR, and RS, shows preliminary clinical application potential for predicting NAC efficacy in patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.